12. Degehardt, T.P., Grass, L., Reddy, S., Thorpe, S.R., Diamandis, E.P., Baynes, J.W. Technical Note: The Serum Concentration of the Advanced Glycation End Product N epsilon-(carboxymethyl)lysine is Increased in Uremia. *Kidney Intl.* (1997) **52**, 1064-1067.

13. Requena, J.R., Ahmed, M.U., Fountain, C.W., Degenhardt, T.P., Reddy, S., Perez, C., Lyons, T.J., Jenkins, A.J., Baynes, J.W., Thorpe, S.R. Carboxymethyethanolamine. A Biomer of Phospholipid Modification during the Maillard Reaction *in Vivo. J. Biol. Chem.* (1997) **272**, 17473-17479.

14. Vlassara, H., Fuh, H., Makita, Z., Krungkrai, S., Cerami, A., Bucala, R. Endogenous Advanced Glycosylation End Products Induce Complex Vascular Dysfunction in Normal Animals: a Model for Diabetic and Complications. *Proc. Natl. Acad. Sci. USA* (1992) **89**, 12043-12047.

15. Tilton, R.G., Chang, K., Hasan, K.S., Smith, S.R., Petrash, J.M., Misko, T.P., Moore, W.M., Currie, M.G., Corbett, J.A., McDaniel, M.L., Williamson, J.R. Prevention of Diabetic Vascular Dysfunction By-guanidine. *Diabetes* (1993) **42**, 221-232.

16. Brownlee, A., Vlassara, H., Kooney, A., Ulrich, P., Cerami, A. Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking. *Science* (1986) **232**, 1629-1632.

17. Brownlee, A., Vlassara H., Cerami A. Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic Complications. *N. Engl. J. Med.* **(1988) 318**, 1315-1321.

18. Stitt, A.W., He, C., Friedman, S., Scher, L., Rossi. P., Ong, L., Founds, H., Li, Y.M., Bucala, R., Vlassara, H. Elevated Modified ApoB in Sera of euglycemic Normo- Lipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs. *Mol. Med.* (1997) **3**, 617-627.

19. Yegin, A., Ozben, T. Serum Glycated Lipoprotein in Type II Diabetic Patients with and without Complications. *Annals Clinic. Biochem.* (1995) **32**, 459-463.

20. Matsui, J., Onuma, T., Tamasawa, N., Suda, T. Effects of Advanced Glycation End Products on the Generation of Macrophage-Mediated Oxidized Low Density Lipoprotein. *J. Diabetes and Complication* (1997) **11**, 338-342.

21. Wrobel, K., Faray-Sevilla, M.E., Nava, L.E., Malacara, J.M. Novel Analytical Approach to Monitoring Advanced Glycosylation End Products in Human Serum with On-Line Spectrophotometric and Spectrofluorometric Detection in a Flow System. *Clin. Chem.* (1997) **43**, 1563-1569.

22. Horiuch, S., Araki, N., Morino, Y. Immunochemical Approach to Characterize Advanced Glycosylation End Products of the Maillard Reaction. *J. Biol. Chem.* (1991) **266**, 7329-7332.

23. Mitsuhashi, T., Vlassara, H., Founds, H.W., Li, Y.M. Standardizing the Immunological Measurement of Advanced Glycation End Products using Normal Human Serum. *Immunol. Methods* (1997) **207**, 79-88.

24. Bunn, H.F., Gabbay, K.H., Gallop, P.M. The Glycosylation of Hemoglobin: Relevance to Diabetes Mellitus. *Science* (1978) **200**, 21-27.

25. Makida, Z., Vlassara, H., Rayfield, E., Cartwright, K., Friedman, E., Rodby, R., Cerami, A., Bucala, R. Hemoglobin AGE: A Circulation Marker of Advanced Glycosylation. *Science* (1992) **258**, 651-653.